References
- Fujii M, Takahashi N, Hayashi H, et al. Purification and characterization of immunosuppressive (IS) substance obtained from ascitic fluids of patients with gastrointestinal cancer. Clin Biochem 1987; 20: 183–189
- Mannami T, Fuchimoto S, Amamiya S, et al. Clinical evaluation of serum immunosuppressive (IS) substance in various diseases. Jpn J Cancer Chemother 1982; 9: 2104–2112
- Sakita M, Yamane T, Kasuga M. Clinical evaluation of the serum level of immunosuppressive acidic protein (IAP) and immunosuppressive substance (IS) in gastric cancer patients. Jpn J Cancer Chemother 1982; 10: 1755–1764
- Noguchi H, Shiozawa I, Sakai Y, et al. Studies of serum levels of immunosuppressive substance (IS) in patients with gynecologic cancer and other diseases. Acta Obstet Gynaecol Jpn 1983; 35: 1931–1937
- Yamashita K, Hayashi H, Mure K, et al. Serum immunosuppressive substance in patients with gynecologic malignancies and in pregnant women. Cancer 1986; 57: 69–74
- Sato H. The List of Transplantable Tumor Maintained in Japan. Japan Cancer Association. 1980; 26–27
- Brunner K T, Engers H D, Cerotinni J C. The 51Cr release assay as used for the quantitative measurement of cell-mediated cytolysis in vitro. In Vitro Methods in Cell-Mediated Immunity, B R Bloom, J David. Academic Press, New York 1976; 423–428
- Kaplan E L, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457–481
- Badger A M, Cooperband S R, Merluzzi V J, et al. Immunosuppressive activity of ascitic fluid from patients with cancer metastatic to the peritoneum. Cancer Res 1977; 37: 1220–1226
- Hess A D, Gall S A, Dawson J R. Inhibition of in vitro lymphocyte function by cystic and ascitic fluids from ovarian cancer patients. Cancer Res 1979; 39: 2381–2389
- Badger A M, Merluzzi V J, Cooperband S R, et al. Immunostimula-tory and immunosuppressive factors in human cancer ascites fluids: Effect on the primary plaque forming response in vitro. Cell Immunol 1976; 27: 126–130
- Tamura K, Shibata Y, Matsuda Y, et al. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res 1981; 41: 3244–3252
- Hamada F, Fuchimoto S, Naomoto Y, et al. Influence of interferon on the suppressive activity of immunosuppressive factor (ISS). Proc Jpn Cancer Assoc 1986; 169
- Oehler J R, Lindsay L R, Nunn M E, et al. Natural cell-mediated cytotoxicity in rats. Int J Cancer 1978; 21: 210–215
- Reynolds C W, Herberman R B. In vivo augmentation of rat natural killer (NK) cell activity. J Immunol 1981; 126: 1581–1585
- Santoli D, Koprowski H. Mechanisms of activation of human natural killer cells against tumor and virus infected cells. Immunol Rev 1979; 44: 125–163
- Onozaki K, Matsushima B, Aggarwal B, et al. Human interleukin I is a cytocidal factor for several tumor cell lines. J Immunol 1985; 135: 3962–3968
- Old U. Tumor necrosis factor (TNF). Science 1985; 230: 630–632
- Kurland J I, Kincade P W, Moore M AS. Regulation of B-lymphocyte clonal proliferation by stimulatory and inhibitory macrophage-derived factors. J Exp Med 1977; 146: 1420–1435
- Pelus L M, Broxmeyer H E, Kurland J I, et al. Regulation of macrophage and granulocyte proliferation. Specifics of prostaglandin E and lactoferrin. J Exp Med 1979; 150: 277–292
- Aune T M, Pierce C W. Mechanisms of action of macrophage-derived suppressor factor produced by soluble immune response suppressor-treated macrophages. J Immunol 1981; 127: 368–371